Carmenta gains licensing option for preeclampsia diagnostic tool

01/28/2013 | GenomeWeb Daily News (free registration)

Carmenta Bioscience has been granted an option to exclusively license technology from Stanford University for undisclosed terms. The Palo Alto, Calif.-based company aims to use the technology to design assays for detecting preeclampsia in pregnant women with or without symptoms of the illness, President and CEO Matthew Cooper said.

View Full Article in:

GenomeWeb Daily News (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Payer Marketing
Avalere Health
Washington, DC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX
Actuary
Meridian Health Plan
Detroit, MI
Chief Financial Officer
B. E. Smith
Miramar, FL